66 related articles for article (PubMed ID: 3329911)
1. Iron and haem complexation studies of 2,3-dihydro-1H-imidazo(1,2-b)pyrazole (IMPY, NSC 51143), a tumour cell ribonucleotide reductase inhibitor.
Ahmet MT; Douglas KT; Silver J; Goddard AJ; Wilman DE
Anticancer Drug Des; 1986 Nov; 1(3):189-95. PubMed ID: 3329911
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and ribonucleotide reductase inhibitory activity of analogues of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY).
Goddard AJ; Orr RM; Stock JA; Wilman DE
Anticancer Drug Des; 1987 Dec; 2(3):235-45. PubMed ID: 3329526
[TBL] [Abstract][Full Text] [Related]
3. Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
Cory JG; Fleischer AE
Cancer Res; 1980 Nov; 40(11):3891-4. PubMed ID: 6781737
[TBL] [Abstract][Full Text] [Related]
4. Clinical toxic effects of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY) with relevant pharmacokinetic parameters.
Neidhart JA; Staubus AE; Young D; King GW; Malspeis L
Cancer Treat Rep; 1980; 64(2-3):251-5. PubMed ID: 7407759
[TBL] [Abstract][Full Text] [Related]
5. Peroxo-type intermediates in class I ribonucleotide reductase and related binuclear non-heme iron enzymes.
Jensen KP; Bell CB; Clay MD; Solomon EI
J Am Chem Soc; 2009 Sep; 131(34):12155-71. PubMed ID: 19663382
[TBL] [Abstract][Full Text] [Related]
6. Density functional study of a micro-1,1-carboxylate bridged Fe(III)-O-Fe(IV) model complex. 2. Comparison with ribonucleotide reductase intermediate X.
Han WG; Lovell T; Liu T; Noodleman L
Inorg Chem; 2004 Jan; 43(2):613-21. PubMed ID: 14731023
[TBL] [Abstract][Full Text] [Related]
7. Studies on the pharmacology and cytokinetics of 2,3-dihydro-1H-imadazo[1,2-b]pyrazole (NSC 51143) with P815 mastocytoma cells.
Allen LM; Thornthwaite JT
Cancer Res; 1980 Nov; 40(11):4059-63. PubMed ID: 6781739
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic implications for the formation of the diiron cluster in ribonucleotide reductase provided by quantitative EPR spectroscopy.
Pierce BS; Elgren TE; Hendrich MP
J Am Chem Soc; 2003 Jul; 125(29):8748-59. PubMed ID: 12862469
[TBL] [Abstract][Full Text] [Related]
9. Use of a chemical trigger for electron transfer to characterize a precursor to cluster X in assembly of the iron-radical cofactor of Escherichia coli ribonucleotide reductase.
Saleh L; Krebs C; Ley BA; Naik S; Huynh BH; Bollinger JM
Biochemistry; 2004 May; 43(20):5953-64. PubMed ID: 15147179
[TBL] [Abstract][Full Text] [Related]
10. EPR study of the mixed-valent diiron sites in mouse and herpes simplex virus ribonucleotide reductases. Effect of the tyrosyl radical on structure and reactivity of the diferric center.
Davydov RM; Davydov A; Ingemarson R; Thelander L; Ehrenberg A; Gräslund A
Biochemistry; 1997 Jul; 36(30):9093-100. PubMed ID: 9230041
[TBL] [Abstract][Full Text] [Related]
11. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
[TBL] [Abstract][Full Text] [Related]
12. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Sato A; Bacon PE; Cory JG
Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
[TBL] [Abstract][Full Text] [Related]
13. A density functional evaluation of an Fe(III)-Fe(IV) model diiron cluster: comparisons with ribonucleotide reductase intermediate X.
Han WG; Lovell T; Liu T; Noodleman L
Inorg Chem; 2003 Apr; 42(8):2751-8. PubMed ID: 12691585
[TBL] [Abstract][Full Text] [Related]
14. O2 activation by non-heme diiron proteins: identification of a symmetric mu-1,2-peroxide in a mutant of ribonucleotide reductase.
Moënne-Loccoz P; Baldwin J; Ley BA; Loehr TM; Bollinger JM
Biochemistry; 1998 Oct; 37(42):14659-63. PubMed ID: 9778340
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
Grant S; Bhalla K; Rauscher F; Cadman E
Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
[TBL] [Abstract][Full Text] [Related]
16. A structural and Mössbauer study of complexes with Fe(2)(micro-O(H))(2) cores: stepwise oxidation from Fe(II)(micro-OH)(2)Fe(II) through Fe(II)(micro-OH)(2)Fe(III) to Fe(III)(micro-O)(micro-OH)Fe(III).
Stubna A; Jo DH; Costas M; Brenessel WW; Andres H; Bominaar EL; Münck E; Que L
Inorg Chem; 2004 May; 43(10):3067-79. PubMed ID: 15132612
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY).
Vogel CL; Denefrio JM; Padgett DC; Silverman MA
Cancer Treat Rep; 1980; 64(10-11):1153-6. PubMed ID: 7459903
[TBL] [Abstract][Full Text] [Related]
18. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
Sato A; Carter GL; Bacon PE; Cory JG
Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
[TBL] [Abstract][Full Text] [Related]
19. DFT calculations of 57Fe Mössbauer isomer shifts and quadrupole splittings for iron complexes in polar dielectric media: applications to methane monooxygenase and ribonucleotide reductase.
Han WG; Liu T; Lovell T; Noodleman L
J Comput Chem; 2006 Sep; 27(12):1292-306. PubMed ID: 16786546
[TBL] [Abstract][Full Text] [Related]
20. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
